Selected article for: "endothelial cell and extracellular matrix"

Author: Zapata, Juan Carlos; Carrion, Ricardo; Patterson, Jean L.; Crasta, Oswald; Zhang, Yan; Mani, Sachin; Jett, Marti; Poonia, Bhawna; Djavani, Mahmoud; White, David M.; Lukashevich, Igor S.; Salvato, Maria S.
Title: Transcriptome Analysis of Human Peripheral Blood Mononuclear Cells Exposed to Lassa Virus and to the Attenuated Mopeia/Lassa Reassortant 29 (ML29), a Vaccine Candidate
  • Document date: 2013_9_12
  • ID: 0epeljaf_52
    Snippet: LASV-induced perturbation of the cross-talk between integrins and the extracellular matrix [67] may contribute to the functional alterations of epithelial and vascular endothelial cells that precede shock and death in LF patients [95] . It is also possible that, during high states of viremia, LASV binds directly to platelets inhibiting their function. After an arterial injury, leukocytes are recruited to the site and there is an increase in ITGAM.....
    Document: LASV-induced perturbation of the cross-talk between integrins and the extracellular matrix [67] may contribute to the functional alterations of epithelial and vascular endothelial cells that precede shock and death in LF patients [95] . It is also possible that, during high states of viremia, LASV binds directly to platelets inhibiting their function. After an arterial injury, leukocytes are recruited to the site and there is an increase in ITGAM expression allowing adhesion of platelets and fibrinogen to the vessel walls [96] . We propose that LASV induction of ITGAM could increase platelet adhesion to tissues and this may explain the decreased number of circulating platelets during hemorrhagic episodes. Platelet-derived endothelial cell growth factor (PD-ECGF) is involved in angiogenesis and wound repair [97] , [98] . The differential expression of all those genes may be contributing to the non-pathogenic phenotype of ML29 and to the pathogenic phenotype of LASV.

    Search related documents:
    Co phrase search for related documents
    • cell growth and differential expression: 1, 2, 3, 4, 5, 6, 7
    • cell growth and directly bind: 1
    • cell growth and endothelial cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell growth and endothelial PD ECGF cell growth factor: 1
    • cell growth and extracellular matrix: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • cell growth and fibrinogen platelet: 1
    • cell growth and function inhibit: 1, 2
    • cell growth and gene differential expression: 1
    • cell growth factor and decreased number: 1
    • cell growth factor and endothelial cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • cell growth factor and endothelial PD ECGF cell growth factor: 1
    • cell growth factor and extracellular matrix: 1, 2, 3, 4
    • cell growth factor and fibrinogen platelet: 1
    • death shock and decreased number: 1
    • decreased number and differential expression: 1, 2
    • decreased number and endothelial cell: 1
    • decreased number and extracellular matrix: 1
    • decreased number and function inhibit: 1
    • differential expression and gene differential expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25